JP2009521206A - 免疫エフェクター活性を有する葉酸受容体アルファ陽性細胞に内部移行する抗体 - Google Patents

免疫エフェクター活性を有する葉酸受容体アルファ陽性細胞に内部移行する抗体 Download PDF

Info

Publication number
JP2009521206A
JP2009521206A JP2008508006A JP2008508006A JP2009521206A JP 2009521206 A JP2009521206 A JP 2009521206A JP 2008508006 A JP2008508006 A JP 2008508006A JP 2008508006 A JP2008508006 A JP 2008508006A JP 2009521206 A JP2009521206 A JP 2009521206A
Authority
JP
Japan
Prior art keywords
antibody
fra
cells
cell
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008508006A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009521206A5 (enExample
Inventor
グラッソ、ルイージ
ニコライデス、ニコラス、シー．
サス、フィリップ、エム．
Original Assignee
モルフォテック、インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by モルフォテック、インク． filed Critical モルフォテック、インク．
Publication of JP2009521206A publication Critical patent/JP2009521206A/ja
Publication of JP2009521206A5 publication Critical patent/JP2009521206A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2008508006A 2005-04-22 2006-04-24 免疫エフェクター活性を有する葉酸受容体アルファ陽性細胞に内部移行する抗体 Pending JP2009521206A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67418505P 2005-04-22 2005-04-22
PCT/US2006/016004 WO2006116592A2 (en) 2005-04-22 2006-04-24 Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011290406A Division JP2012100675A (ja) 2005-04-22 2011-12-29 免疫エフェクター活性を有する葉酸受容体アルファ陽性細胞に内部移行する抗体

Publications (2)

Publication Number Publication Date
JP2009521206A true JP2009521206A (ja) 2009-06-04
JP2009521206A5 JP2009521206A5 (enExample) 2011-09-01

Family

ID=37215502

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008508006A Pending JP2009521206A (ja) 2005-04-22 2006-04-24 免疫エフェクター活性を有する葉酸受容体アルファ陽性細胞に内部移行する抗体
JP2011290406A Pending JP2012100675A (ja) 2005-04-22 2011-12-29 免疫エフェクター活性を有する葉酸受容体アルファ陽性細胞に内部移行する抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011290406A Pending JP2012100675A (ja) 2005-04-22 2011-12-29 免疫エフェクター活性を有する葉酸受容体アルファ陽性細胞に内部移行する抗体

Country Status (6)

Country Link
US (5) US20060239910A1 (enExample)
EP (2) EP2172487A1 (enExample)
JP (2) JP2009521206A (enExample)
AU (1) AU2006241099B2 (enExample)
CA (1) CA2607444C (enExample)
WO (1) WO2006116592A2 (enExample)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012128377A1 (ja) 2011-03-18 2012-09-27 国立大学法人鹿児島大学 膵臓癌の治療用及び診断用の組成物
JP2013524773A (ja) * 2010-02-24 2013-06-20 イミュノジェン， インコーポレイテッド フォレート受容体１抗体及びそのイムノコンジュゲート及び使用
JP2014505012A (ja) * 2010-10-20 2014-02-27 モーフォテック， インコーポレイテッド 抗葉酸受容体アルファ抗体の糖型
KR20140027969A (ko) * 2011-04-01 2014-03-07 이뮤노젠 아이엔씨 Folr1 암 치료의 효능을 증가시키기 위한 방법
JP2014509841A (ja) * 2011-01-18 2014-04-24 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 癌を治療するための組成物および方法
WO2014087863A1 (ja) * 2012-12-07 2014-06-12 協和発酵キリン株式会社 抗ｆｏｌｒ１抗体
JP2018029605A (ja) * 2011-07-15 2018-03-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗葉酸受容体アルファ抗体およびその使用
JP2018036270A (ja) * 2010-11-05 2018-03-08 モルフォテック、インク． 葉酸受容体アルファ発現癌の診断および予後マーカーとしての葉酸受容体アルファ
JP2020018325A (ja) * 2012-08-31 2020-02-06 イミュノジェン， インコーポレイテッド 葉酸受容体１の検出のための診断分析およびキット

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1626991A2 (en) * 2003-05-23 2006-02-22 Morphotek, Inc. Anti alpha-folate-receptor-tetramer antibodies
US20050054048A1 (en) * 2003-07-29 2005-03-10 Luigi Grasso Antibodies and methods for generating genetically altered antibodies with enhanced effector function
CA2556027C (en) 2004-02-12 2015-11-24 Morphotek, Inc. Monoclonal antibodies that specifically block biological activity of a tumor antigen
EP2322560B1 (en) 2005-03-10 2013-09-04 Morphotek, Inc. Anti-mesothelin antibodies
EP2172487A1 (en) 2005-04-22 2010-04-07 Morphotek Inc. Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells
US20090191202A1 (en) * 2005-09-29 2009-07-30 Jamieson Catriona Helen M Methods for manipulating phagocytosis mediated by CD47
PT3056515T (pt) * 2008-01-15 2019-07-19 Univ Leland Stanford Junior Métodos para manipulação da fagocitose mediada por cd47
US11072655B2 (en) 2008-01-15 2021-07-27 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
CA2711370C (en) 2008-01-15 2017-06-13 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
AU2014203172B2 (en) * 2010-02-24 2016-03-10 Immunogen, Inc. Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof
AU2011252851B2 (en) 2010-05-14 2016-10-06 The Board Of Trustees Of The Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to CD47
US9598489B2 (en) 2012-10-05 2017-03-21 The Trustees Of The Univeristy Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
BR112015031950A2 (pt) 2013-06-20 2017-07-25 Morphotek Inc métodos para tratamento de câncer de ovário
NZ717140A (en) 2013-08-30 2022-05-27 Immunogen Inc Antibodies and assays for detection of folate receptor 1
SG11201704056XA (en) 2014-11-20 2017-06-29 Hoffmann La Roche Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists
RS61010B1 (sr) 2014-11-20 2020-11-30 Hoffmann La Roche Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije protiv folr1 i cd3
ES2808853T3 (es) 2014-11-20 2021-03-02 Hoffmann La Roche Cadenas ligeras comunes y procedimientos de uso
CA2983126A1 (en) * 2015-04-17 2016-10-20 Morphotek, Inc. Methods for treating lung cancer
CN122075735A (zh) 2015-09-17 2026-05-26 伊缪诺金公司 包含抗folr1免疫缀合物的治疗组合
US9650441B2 (en) 2015-09-21 2017-05-16 Erasmus University Medical Center Anti-CD47 antibodies and methods of use
EP3765521A4 (en) 2018-03-13 2022-03-23 Phanes Therapeutics, Inc. ANTI-FOLATE RECEPTOR-1 ANTIBODIES AND USES THEREOF
KR102275930B1 (ko) * 2018-03-14 2021-07-12 (주)알테오젠 Folr1에 특이적으로 결합하는 항체 및 그의 용도
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
JP7426661B2 (ja) * 2018-12-17 2024-02-02 株式会社カネカ 特定抗原特異的抗体を産生する細胞のスクリーニング方法
SG11202111109UA (en) 2019-04-29 2021-11-29 Immunogen Inc Biparatopic fr-alpha antibodies and immunoconjugates
WO2024104431A1 (zh) * 2022-11-16 2024-05-23 迈威(上海)生物科技股份有限公司 一种靶向FRα的抗体或其抗原结合片段及其应用
US12649790B2 (en) 2023-07-03 2026-06-09 Medicovestor, Inc. Proteins that bind SP17 including fully-human anti-SP17 antibodies
US12624097B2 (en) 2023-07-03 2026-05-12 Medicovestor, Inc. Nucleic acids, vectors, and cells that encode anti-Sp17 antibodies and other Sp17 binding proteins
US12673991B2 (en) 2023-12-26 2026-07-07 Medicovestor, Inc. Methods of crosslinking IgG
US12600795B2 (en) 2023-12-26 2026-04-14 Medicovestor, Inc. Oligomeric IgG for immunotherapeutics and diagnostics
US12121587B1 (en) 2023-12-26 2024-10-22 Medicovestor, Inc. Dimeric antibodies
US12378314B1 (en) 2024-02-02 2025-08-05 Medicovestor, Inc. Proteins that bind folate receptor alpha including fully-human antibodies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952484A (en) * 1994-03-08 1999-09-14 Sloan-Kettering Cancer Center Recombinant human anti-LK26 antibodies
WO2004113388A2 (en) * 2003-05-23 2004-12-29 Morphotek, Inc. Anti alpha - folate - receptor - tetramer antibodies

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4694778A (en) * 1984-05-04 1987-09-22 Anicon, Inc. Chemical vapor deposition wafer boat
US4851332A (en) 1985-04-01 1989-07-25 Sloan-Kettering Institute For Cancer Research Choriocarcinoma monoclonal antibodies and antibody panels
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5006470A (en) 1987-04-16 1991-04-09 Sloan-Kettering Institute For Cancer Research Human monoclonal antibodies to cell surface antigens of melanoma
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5688488A (en) 1989-04-03 1997-11-18 Purdue Research Foundation Composition and method for tumor imaging
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DK0554356T3 (da) * 1990-10-12 1999-06-14 Us Health Monoklonalt antistof
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6191268B1 (en) * 1993-12-17 2001-02-20 Dana-Farber Cancer Institute Compositions and methods relating to DNA mismatch repair genes
NZ281023A (en) * 1994-01-27 1998-04-27 Human Genome Sciences Inc Human dna mismatch repair proteins and coding sequences
DE19513676A1 (de) * 1995-04-11 1996-10-17 Behringwerke Ag Cytoplasmatische Expression von Antikörpern, Antikörperfragmenten und Antikörperfragmentfusionsmolekülen in E.coli
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
WO1997025068A2 (en) 1996-01-05 1997-07-17 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Mesothelin antigen and methods and kits for targeting it
BR9708910A (pt) 1996-05-04 1999-08-03 Zeneca Ltd Anticorpo conjugado sequência de polinucleotídeos vetor célula hospedeira hibridoma composição farmacêutica processos para fabricar um anticorpo ou um conjugado e para tratar um humano ou animal em necessidade deste tratamento
US6809184B1 (en) * 1997-12-01 2004-10-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use
US6146894A (en) 1998-04-14 2000-11-14 The Johns Hopkins University Method for generating hypermutable organisms
US6365410B1 (en) * 1999-05-19 2002-04-02 Genencor International, Inc. Directed evolution of microorganisms
MXPA01011950A (es) * 1999-05-27 2002-05-06 Gov Health & Human Serv Inmunoconjugados que tienen alta afinidad de enlace.
US6808894B1 (en) * 2000-11-07 2004-10-26 Morphotek, Inc. Methods for generating genetically altered antibody producing cell lines with improved antibody characteristics
DE60045652D1 (de) 2000-11-07 2011-03-31 Morphotek Inc Verfahren zur Erzeugung von genetisch veränderten Antikörperherstellungszelllinien mit verbesserter Antikörpereigenschaft
JP5036119B2 (ja) 2001-01-15 2012-09-26 モーフオテク・インコーポレーテツド ミスマッチ修復の化学阻害剤
IL158532A0 (en) 2001-05-02 2004-05-12 Purdue Research Foundation Treatment and diagnosis of macrophage mediated disease
EP1258255A1 (en) 2001-05-18 2002-11-20 Boehringer Ingelheim International GmbH Conjugates of an antibody to CD44 and a maytansinoid
EA200301169A1 (ru) 2001-05-18 2004-06-24 Бёрингер Ингельхайм Интернациональ Гмбх АНТИТЕЛА, СПЕЦИФИЧЕСКИЕ В ОТНОШЕНИИ CD44v6
GB2403222A (en) 2002-04-01 2004-12-29 Utah Ventures Ii L P Tissue-specific endothelial membrane proteins
AU2003256642B2 (en) 2002-07-19 2008-05-01 Morphotek, Inc. Methods for generating enhanced antibody-producing cell lines with improved growth characteristics
US20050054048A1 (en) 2003-07-29 2005-03-10 Luigi Grasso Antibodies and methods for generating genetically altered antibodies with enhanced effector function
CA2534659A1 (en) 2003-08-05 2005-02-17 Morphotek, Inc. A variant cell surface molecule associated with cancer
CA2556027C (en) * 2004-02-12 2015-11-24 Morphotek, Inc. Monoclonal antibodies that specifically block biological activity of a tumor antigen
EA200700751A1 (ru) 2004-10-05 2008-06-30 Элан Фарма Интернэшнл Лимитед Способы и композиции для улучшения продуцирования рекомбинантного белка
EP2322560B1 (en) * 2005-03-10 2013-09-04 Morphotek, Inc. Anti-mesothelin antibodies
DE602006012816D1 (de) 2005-03-30 2010-04-22 Endocyte Inc Tifizierung von zellulären folat vitamin rezeptoren
EP2172487A1 (en) 2005-04-22 2010-04-07 Morphotek Inc. Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells
US8795633B2 (en) 2005-09-23 2014-08-05 Purdue Research Foundation Multiphoton in vivo flow cytometry method and device
US20070154916A1 (en) 2005-11-04 2007-07-05 Johji Inazawa Method for detecting cancer and a method for suppressing cancer
EP1900752A1 (en) 2006-09-15 2008-03-19 DOMPE' pha.r.ma s.p.a. Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
JP2010509570A (ja) 2006-11-03 2010-03-25 パーデュー・リサーチ・ファウンデーション エクスビボフローサイトメトリーの方法および装置
BRPI0812970A2 (pt) 2007-06-25 2019-09-24 Endocyte Inc conjugados contendo espaçadores hidrofílicos
WO2009032974A2 (en) 2007-09-06 2009-03-12 Tripath Imaging, Inc. Nucleic acid-based methods for the detection of ovarian cancer
GB0725077D0 (en) 2007-12-21 2008-01-30 Univ Murcia Antifolate com[ounds for the treatment of melanoma
WO2009132081A2 (en) 2008-04-24 2009-10-29 The Research Foundation Of State University Of New York Monoclonal antibody-based targeting of folate receptors
KR20140032944A (ko) * 2010-10-20 2014-03-17 모르포테크, 인크. 항폴레이트 수용체 알파 항체 당형태
SG189957A1 (en) * 2010-11-05 2013-06-28 Morphotek Inc Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers
JP6122948B2 (ja) * 2012-05-15 2017-04-26 モルフォテック， インコーポレイテッド 胃癌の治療のための方法
CN104884617B (zh) * 2012-12-07 2019-02-19 协和发酵麒麟株式会社 抗folr1抗体
BR112015031950A2 (pt) * 2013-06-20 2017-07-25 Morphotek Inc métodos para tratamento de câncer de ovário
CA2983126A1 (en) * 2015-04-17 2016-10-20 Morphotek, Inc. Methods for treating lung cancer
MY199595A (en) * 2016-03-02 2023-11-08 Eisai R&D Man Co Ltd Eribulin-based antibody-drug conjugates and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952484A (en) * 1994-03-08 1999-09-14 Sloan-Kettering Cancer Center Recombinant human anti-LK26 antibodies
WO2004113388A2 (en) * 2003-05-23 2004-12-29 Morphotek, Inc. Anti alpha - folate - receptor - tetramer antibodies

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022191500A (ja) * 2010-02-24 2022-12-27 イミュノジェン， インコーポレイテッド フォレート受容体１抗体及びそのイムノコンジュゲート及び使用
JP2013524773A (ja) * 2010-02-24 2013-06-20 イミュノジェン， インコーポレイテッド フォレート受容体１抗体及びそのイムノコンジュゲート及び使用
JP2024138308A (ja) * 2010-02-24 2024-10-08 イミュノジェン， インコーポレイテッド フォレート受容体１抗体及びそのイムノコンジュゲート及び使用
JP7515228B2 (ja) 2010-02-24 2024-07-12 イミュノジェン， インコーポレイテッド フォレート受容体１抗体及びそのイムノコンジュゲート及び使用
JP7167228B2 (ja) 2010-02-24 2022-11-08 イミュノジェン， インコーポレイテッド フォレート受容体１抗体及びそのイムノコンジュゲート及び使用
JP2016000729A (ja) * 2010-02-24 2016-01-07 イミュノジェン， インコーポレイテッド フォレート受容体１抗体及びそのイムノコンジュゲート及び使用
JP2021100430A (ja) * 2010-02-24 2021-07-08 イミュノジェン， インコーポレイテッド フォレート受容体１抗体及びそのイムノコンジュゲート及び使用
JP2019213522A (ja) * 2010-02-24 2019-12-19 イミュノジェン， インコーポレイテッド フォレート受容体１抗体及びそのイムノコンジュゲート及び使用
TWI622402B (zh) * 2010-02-24 2018-05-01 免疫遺傳股份有限公司 葉酸受體１抗體類和免疫共軛物類及彼等之用途
JP2014505012A (ja) * 2010-10-20 2014-02-27 モーフォテック， インコーポレイテッド 抗葉酸受容体アルファ抗体の糖型
JP2018036270A (ja) * 2010-11-05 2018-03-08 モルフォテック、インク． 葉酸受容体アルファ発現癌の診断および予後マーカーとしての葉酸受容体アルファ
JP2014509841A (ja) * 2011-01-18 2014-04-24 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 癌を治療するための組成物および方法
WO2012128377A1 (ja) 2011-03-18 2012-09-27 国立大学法人鹿児島大学 膵臓癌の治療用及び診断用の組成物
KR20210088746A (ko) * 2011-04-01 2021-07-14 이뮤노젠 아이엔씨 Folr1 암 치료의 효능을 증가시키기 위한 방법
KR101982317B1 (ko) 2011-04-01 2019-05-27 이뮤노젠 아이엔씨 Folr1 암 치료의 효능을 증가시키기 위한 방법
KR20190058696A (ko) * 2011-04-01 2019-05-29 이뮤노젠 아이엔씨 Folr1 암 치료의 효능을 증가시키기 위한 방법
KR20140027969A (ko) * 2011-04-01 2014-03-07 이뮤노젠 아이엔씨 Folr1 암 치료의 효능을 증가시키기 위한 방법
JP2014513068A (ja) * 2011-04-01 2014-05-29 イミュノジェン， インコーポレイテッド Ｆｏｌｒ１がん治療の有効性を増加させるための方法
KR102101160B1 (ko) 2011-04-01 2020-04-16 이뮤노젠 아이엔씨 Folr1 암 치료의 효능을 증가시키기 위한 방법
KR102489185B1 (ko) 2011-04-01 2023-01-17 이뮤노젠 아이엔씨 Folr1 암 치료의 효능을 증가시키기 위한 방법
JP2016147901A (ja) * 2011-04-01 2016-08-18 イミュノジェン， インコーポレイテッド Ｆｏｌｒ１がん治療の有効性を増加させるための方法
JP2018029605A (ja) * 2011-07-15 2018-03-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗葉酸受容体アルファ抗体およびその使用
JP2022022420A (ja) * 2012-08-31 2022-02-03 イミュノジェン， インコーポレイテッド 葉酸受容体１の検出のための診断分析およびキット
JP7289346B2 (ja) 2012-08-31 2023-06-09 イミュノジェン， インコーポレイテッド 葉酸受容体１の検出のための診断分析およびキット
JP2023111942A (ja) * 2012-08-31 2023-08-10 イミュノジェン， インコーポレイテッド 葉酸受容体１の検出のための診断分析およびキット
JP2020018325A (ja) * 2012-08-31 2020-02-06 イミュノジェン， インコーポレイテッド 葉酸受容体１の検出のための診断分析およびキット
US9207238B2 (en) 2012-12-07 2015-12-08 Kyowa Hakko Kirin Co., Ltd. Anti-FOLR1 antibody
WO2014087863A1 (ja) * 2012-12-07 2014-06-12 協和発酵キリン株式会社 抗ｆｏｌｒ１抗体
JPWO2014087863A1 (ja) * 2012-12-07 2017-01-05 協和発酵キリン株式会社 抗ｆｏｌｒ１抗体
US9695237B2 (en) 2012-12-07 2017-07-04 Kyowa Hakko Kirin Co., Ltd Anti-FOLR1 antibody

Also Published As

Publication number Publication date
US9522195B2 (en) 2016-12-20
WO2006116592A2 (en) 2006-11-02
US9144614B2 (en) 2015-09-29
AU2006241099A1 (en) 2006-11-02
US20170073425A1 (en) 2017-03-16
US10253106B2 (en) 2019-04-09
CA2607444C (en) 2015-03-10
CA2607444A1 (en) 2006-11-02
US20120171200A1 (en) 2012-07-05
JP2012100675A (ja) 2012-05-31
AU2006241099B2 (en) 2012-04-19
EP1879922A2 (en) 2008-01-23
US20090324594A1 (en) 2009-12-31
US8124083B2 (en) 2012-02-28
WO2006116592A9 (en) 2007-03-22
WO2006116592A3 (en) 2007-04-19
EP2172487A1 (en) 2010-04-07
US20160058885A1 (en) 2016-03-03
US20060239910A1 (en) 2006-10-26

Similar Documents

Publication Publication Date Title
US10253106B2 (en) Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
EP2322560B1 (en) Anti-mesothelin antibodies
JP2012100676A (ja) 免疫エフェクター活性を有するエンドシアリン細胞に内部移行する抗体
AU2012254877B2 (en) Anti-mesothelin antibodies
AU2017239474B2 (en) Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
AU2012205242B2 (en) Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090423

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090423

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20090609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090624

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20110520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110712

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110712

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110830

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111128

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111229

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120404